December 2021 updates to the website

The website has now been updated following November's LSCMMG

The following guidelines have been added/updated:

Overactive bladder guidance - New (Agreed, However awaiting further information prior to publishing) 

Dapagliflozin for T1 DM – TA 597 - Withdrawn and removed from the website

The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:

Glycopyrronium - Hypersalivation in patients with Non - Parkinson's Disease

Upadacitinib - Upadacitinib for treating moderate rheumatoid arthritis (NICE TA744)